AzTrials
AzTrials

Borderline Intellectual Functioning (BIF)NCT07625592

Co-design of an AI Rehabilitation Program for Children With Borderline Intellectual Disorder

An observational study of Borderline Intellectual Functioning (BIF) and Intellectual Disability, run by Samsung Medical Center at 1 site in South Korea.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Co-design of an AI Rehabilitation Program for Children With Borderline Intellectual Disorder Read more about this study

Who is it for?
Ages 7 years and older
What is being tested?
Tablet-Based AI Cognitive and Language Rehabilitation Program
How many people
30 participants
Where
1 siteSouth Korea
Study dates
24 Apr 2026to 31 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 7 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The study population includes school-aged children with borderline intellectual disorder who have prior experience using a tablet-based AI cognitive and language rehabilitation program, their legal guardians, and professionals involved in the development or clinical application of rehabilitation programs for children with borderline intellectual disorder.

Who may be able to join

  • School-aged children aged 7 to under 16 years with borderline intellectual disorder who have experienced the tablet-based AI cognitive and language rehabilitation program at least once
  • Legal guardians of eligible children
  • Developers of the AI rehabilitation program or professionals with expertise in cognition, language, learning, or rehabilitation for children with borderline intellectual disorder

Who cannot join

  • Individuals who are unable to participate in interviews or workshops due to communication difficulties or inability to provide informed consent/assent

Trial locations and contacts

1 site in 1 country.

South Korea1 site
  • Samsung Medical Center

    Seoul, Seoul, 06351

Other trials in South Korea

About this study

Official title: Multidisciplinary Experience-Based Collaborative Design (Co-design) Study of a Tablet-Based AI Cognitive and Language Rehabilitation Program for School-Aged Children With Borderline Intellectual Disorder

Co-design of an AI Rehabilitation Program for Children With Borderline Intellectual Disorder

Read the detailed description

This study aims to co-design a tablet-based artificial intelligence (AI) cognitive and language rehabilitation program for school-aged children with borderline intellectual disorder using an experience-based collaborative design (EBCD) approach. Children with prior experience using the program, their legal guardians, and relevant professionals will participate in interviews and collaborative workshops to identify user needs and improve program usability.

Being tested
Tablet-Based AI Cognitive and Language Rehabilitation Program
Keywords
Borderline Intellectual Disorder, Artificial Intelligence, Cognitive Rehabilitation, Language Rehabilitation, Experience-Based Co-Design
Medical subject headings
Intellectual Disability

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tablet-Based AI Cognitive and Language Rehabilitation ProgramBehavioural

    A tablet-based artificial intelligence (AI) cognitive and language rehabilitation program previously experienced by children with borderline intellectual disorder. The study collects user and provider experiences through interviews and collaborative workshops to support experience-based co-design and program improvement.

Study groups in NCT07625592
Study groupRoleWhat they receive
Children With Borderline Intellectual DisorderSchool-aged children aged 7 to under 16 years with borderline intellectual disorder who have experienced the tablet-based AI cognitive and language rehabilitation program at least once.
Receives: Behavioral: Tablet-Based AI Cognitive and Language Rehabilitation Program
Legal GuardiansLegal guardians of children with borderline intellectual disorder who have experienced the tablet-based AI cognitive and language rehabilitation program.
Developers and ProfessionalsDevelopers of the AI rehabilitation program and professionals with clinical expertise in cognition, language, learning, or rehabilitation for children with borderline intellectual disorder.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Qualitative Themes Regarding Participant Experiences with the AI Rehabilitation Program

    Qualitative themes regarding participant experiences with the tablet-based AI cognitive and language rehabilitation program will be identified. In-depth interviews will be conducted with users with borderline intellectual functioning and their legal guardians to explore usability and satisfaction. Additionally, focus group discussions with developers and clinical professionals will be held to gather multidisciplinary insights. All qualitative data will be analyzed using qualitative content analysis to extract key core themes. Therefore, there is no quantitative scale used. Results will be reported as identified thematic categories.

    Measured: Once per participant/professional during the interview or workshop session conducted post-intervention (overall data collection through December 2026).

Secondary outcomes (2)
  1. Perceived Barriers and Challenges to AI Rehabilitation Program Use

    Participant-perceived barriers and challenges related to the use of the tablet-based AI cognitive and language rehabilitation program will be identified. Through semi-structured qualitative interviews with users with borderline intellectual functioning and their legal guardians, as well as focus group discussions with developers and clinical professionals, potential obstacles to program adherence, technical difficulties, and clinical limitations will be explored. All qualitative data will be analyzed using thematic analysis to extract core barrier themes. Therefore, there is no quantitative scale used. Results will be reported as identified thematic categories.

    Measured: Once per participant/professional during the interview or workshop session conducted post-intervention (overall data collection through December 2026).

  2. Co-design Recommendations for AI Rehabilitation Program Improvement

    Recommendations for the improvement and optimization of the tablet-based AI cognitive and language rehabilitation program will be developed. Through collaborative co-design workshops involving users with borderline intellectual functioning, their legal guardians, developers, and clinical professionals, actionable insights regarding feature enhancements and interface modifications will be explored. All qualitative data gathered from the workshops will be analyzed using thematic analysis to synthesize core design recommendations. Therefore, there is no quantitative scale used. Results will be reported as identified thematic categories and recommendation frameworks.

    Measured: Once per participant/professional during the co-design workshop sessions conducted during the study period (overall data collection through December 2026).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jun 2026
  2. Study start24 Apr 2026
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07625592
Sponsor's protocol ID
2025-12-062
Status last verified
May 2026
First submitted
12 May 2026
Last updated
4 Jun 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Borderline Intellectual Functioning (BIF) and Intellectual Disability, run by Samsung Medical Center at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Qualitative Themes Regarding Participant Experiences with the AI Rehabilitation Program (time frame: Once per participant/professional during the interview or workshop session conducted post-intervention (overall data collection through December 2026).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in